The purpose of this study is to identify important associations between complete and comprehensive clinical, laboratory, and genomic data derived from patients and tumor specimens, with prospectively recorded clinical outcomes. The investigators also hope to move beyond simple risk factor associations as previously described, to develop a composite score specifically for KS recurrence or progression, analogous to widely used risk scores that are used to direct up-front treatment of other cancers. In so doing, the investigators will draw on extremely granular data to prospectively identify patients who are most likely to benefit from new treatments.
No linked publications found in PubMed
Inclusion Criteria: * Histologically confirmed KS initiating chemotherapy at Lighthouse Trust or the Kamuzu Central Hospital (KCH) Cancer Clinic * HIV positive (confirmed at any time point prior by local standard of care assay) on or off ART * Age ≥18 years * Residence \<200 kilometers from KCH * Able to understand and comply with study procedures for the entire length of the study * Subject able to understand and provide written consent in English or Chichewa Informed consent reviewed and signed by patient Exclusion Criteria: * Failure to meet inclusion criteria listed above. * Specifically, pregnancy and breastfeeding are not exclusion criteria given the observational nature of the study with diagnostic and treatment interventions administered according to local standards of care. * KS relapse disease as defined by a prior KS diagnosis within 1 year prior to enrollment.